Tumor suppressors govern insulin-like growth factor signaling pathways: Implications in metabolism and cancer

Oncogene

Volumn 31, Issue 22, 2012, Pages 2703-2714

  Werner, H ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

BRCA1; IGF; IGF 1 receptor; Insulin like growth factors; P53; Tumor suppressors

Indexed keywords

ADENOSINE TRIPHOSPHATE; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST CANCER GENE 1; DNA; GLUCOSE; GROWTH HORMONE; GROWTH HORMONE RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INSULIN RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; PROTEIN P63; PROTEIN P73; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

BREAST CANCER; CANCER RISK; CARCINOGENESIS; DEREGULATION; DNA DAMAGE; DROSOPHILA; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; GLYCOLYSIS; GROWTH RETARDATION; HUMAN; INTRAUTERINE GROWTH RETARDATION; KIDNEY CANCER; LOSS OF FUNCTION MUTATION; METABOLIC REGULATION; METABOLISM; METABOLOMICS; NEOPLASM; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN INTERACTION; PROTEIN SYNTHESIS; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; ZINC FINGER MOTIF;

ANIMALS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; NEOPLASMS; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84861682298     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.447     Document Type: Review

References (114)

1. Abramovitch S, Glaser T, Ouchi T, Werner H. (2003). BRCA1-Sp1 interactions in transcriptional regulation of the IGF-IR gene. FEBS Lett 541: 149-154. (Pubitemid 36428934)
2. Abuzzahab MJ, Schneider A, Goddard A, Grigorescu F, Lautier C, Keller E et al. (2003). IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. N Engl J Med 349: 2211-2222. (Pubitemid 37485137)
3. Aylon Y, Oren M. (2011). New plays in the p53 theater. Curr Opinion Genet Dev 38: 86-92.
4. Baserga R, Peruzzi F, Reiss K. (2003). The IGF-1 receptor in cancer biology. Int J Cancer 107: 873-877. (Pubitemid 37429826)
5. Belfiore A, Frasca F. (2008). IGF and insulin receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia 13: 381-406.
6. Belfiore A, Malaguarnera R. (2011). Insulin receptor and cancer. Endocrine Related Cancer 18: R125-R147.
7. Bentov I, Narla G, Schayek H, Akita K, Plymate SR, LeRoith D et al. (2008). Insulin-like growth factor-I regulates kruppel-like factor-6 gene expression in a p53-dependent manner. Endocrinology 149: 1890-1897. (Pubitemid 351468329)
8. Bentov I, Werner H. (2004). IGF, IGF receptor and overgrowth syndromes. Pediatr Endocrinol Rev 1: 352-360. (Pubitemid 40204047)
9. Bondy CA, Werner H, Roberts Jr CT, LeRoith D. (1990). Cellular pattern of insulin-like growth factor I (IGF-I) and type I IGF receptor gene expression in early organogenesis: comparison with IGF-II gene expression. Mol Endocrinol 4: 1386-1398. (Pubitemid 20371439)
10. Boulton SJ. (2006). Cellular functions of the BRCA tumoursuppressor proteins. Biochem Soc Trans 34: 633-645. (Pubitemid 44796392)
11. Brase JC, Wuttig D, Kuner R, Sueltmann H. (2010). Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer 9: 306.
12. Bruchim I, Attias Z, Werner H. (2009). Targeting the IGF1 axis in cancer proliferation. Exp Opinion Ther Targets 13: 1179-1192.
13. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR et al. (1995). Induction of the growth inhibitor IGFbinding protein 3 by p53. Nature 377: 1367-1373.
14. Cairns RA, Harris IS, Mak TW. (2011). Regulation of cancer cell metabolism. Nat Rev Cancer 11: 85-95.
15. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P et al. (1998). Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279: 563-566. (Pubitemid 28067285)
16. Chott A, Sun Z, Morganstern D, Pan J, Li T, Susani M et al. (1999). Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of type 1 insulin-like growth factor receptor. Am J Pathol 155: 1271-1279. (Pubitemid 29488934)
17. Christofori G, Naik P, Hanahan D. (1994). A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature 369: 414-418.
18. Conaway RC, Conaway JW. (2002). The von Hippel-Lindau tumor suppressor complex and regulation of hypoxia-inducible transcription. Adv Cancer Res 85: 1-12.
19. Dossus L, Kaaks R. (2008). Nutrition, metabolic factors and cancer risk. Best Pract Res Clin Endocrinol Metab 22: 551-571.
20. Eshet R, Werner H, Klinger B, Silbergeld A, Laron Z, LeRoith D et al. (1993). Up-regulation of insulin-like growth factor-I (IGF-I) receptor gene expression in patients with reduced serum IGF-I levels. J Mol Endocrinol 10: 115-120. (Pubitemid 23100293)
21. Finkeltov I, Kuhn S, Glaser T, Idelman G, Wright JJ, Roberts Jr CT et al. (2002). Transcriptional regulation of IGF-I receptor gene expression by novel isoforms of the EWS-WT1 fusion protein. Oncogene 21: 1890-1898. (Pubitemid 34259192)
22. Gerald WL, Haber DA. (2005). The EWS-WT1 gene fusion in desmoplastic small round cell tumor. Sem Cancer Biol 15: 197-205.
23. Gerald WL, Ladanyi M, de Alava E, Cuatrecasas M, Kushner BH, LaQuaglia MP et al. (1998). Clinical, pathologic, and molecular spectrum of tumors associated with t(11;22)(p13;q12): desmoplastic small round-cell tumor and its variants. J Clin Oncol 16: 3028-3036. (Pubitemid 28417423)
24. Girnita L, Girnita A, Larsson O. (2003). Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor-1 receptor. Proc Natl Acad Sci USA 100: 8247-8252. (Pubitemid 36842530)
25. Gualberto A, Pollak M. (2009). Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 28: 3009-3021.
26. Guertin DA, Sabatini DM. (2007). Defining the role of mTOR in cancer. Cancer Cell 12: 9-22. (Pubitemid 47001784)
27. Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, Wei M, Madia F, Cheng CW et al. (2011). Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med 3: 70ra13.
28. Guler HP, Schmid C, Zapf J, Froesch ER. (1989). Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects. Proc Natl Acad Sci USA 86: 2868-2872. (Pubitemid 19112641)
29. Guler HP, Zapf J, Froesch ER. (1987). Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med 317: 137-140. (Pubitemid 17092150)
30. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B et al. (1998). Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351: 1393-1396. (Pubitemid 28209997)
31. Happerfield LC, Miles DW, Barnes DM, Thomsen LL, Smith P, Hanby AM. (1997). The localization of the insulin-like growth factor receptor 1 (IGFR-1) in benign and malignant breast tissue. J Pathol 183: 412-417. (Pubitemid 27509247)
32. Harrington EA, Bennett MR, Fanidi A, Evan GI. (1994). c-Mycinduced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J 13: 3286-3295. (Pubitemid 24226943)
33. Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM. (2002). Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 62: 2942-2950. (Pubitemid 34525783)
34. Hernandez-Sanchez C, Werner H, Roberts Jr CT, Woo EJ, Hun DW, Rosenthal SM et al. (1997). Differential regulation of IGF-I receptor gene expression by IGF-I and basic fibroblast growth factor. J Biol Chem 272: 4663-4670. (Pubitemid 27090007)
35. Heron-Milhavet L, LeRoith D. (2002). Insulin-like growth factor I induces MDM2-dependent degradation of p53 via the p38 MAPK pathway in response to DNA damage. J Biol Chem 277: 15600-15606. (Pubitemid 34967830)
36. Hornstein E, Shomron N. (2006). Canalization of development by microRNAs. Nat Genet 38(Suppl): S20-S24.
37. Huff V. (2011). Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene. Nat Rev Cancer 11: 111-121.
38. Idelman G, Glaser T, Roberts Jr CT, Werner H. (2003). WT1-p53 interactions in IGF-I receptor gene regulation. J Biol Chem 278: 3474-3482. (Pubitemid 36801264)
39. Irwin MS, Kaelin WG (2001). p53 family update: p73 and p63 develop their own identities. Cell Growth Differ 12 337-349. (Pubitemid 32685635)
40. Jacob R, Barrett E, Plewe G, Fagin JD, Sherwin RS. (1989). Acute effects of insulin-like growth factor I on glucose and amino acid metabolism in the awake fasted rat. Comparison with insulin. J Clin Invest 83: 1717-1723. (Pubitemid 19124130)
41. Jiang L, Liu X, Chen Z, Jin Y, Heidbreder CE, Kolokythas A et al. (2010). MicroRNA-7 targets IGF1R (insulin-like growth factor 1 receptor) in tongue squamous cell carcinoma cells. Biochem J 432: 199-205.
42. Kim SO, Park JG, Lee YI. (1996). Increased expression of the insulinlike growth factor I (IGF-I) receptor gene in hepatocellular carcinoma cell lines: implications of IGF-I receptor gene activation by hepatitis B virus X gene product. Cancer Res 56: 3831-3836. (Pubitemid 26272036)
43. Klammt J, Kiess W, Pfaffle R. (2011). IGF1R mutations as cause of SGA. Best Pract Res Clin Endocrinol Metab 25: 191-206.
44. Klammt J, Pfaffle R, Werner H, Kiess W. (2008). IGF signaling defects as causes of growth failure and IUGR. Trends Endocrinol Metab 19: 197-205. (Pubitemid 351993012)
45. Kozma LM, Weber MJ. (1990). Constitutive phosphorylation of the receptor for insulin-like growth factor I in cells transformed by the src oncogene. Mol Cell Biol 10: 3626-3634.
46. Kruis T, Klammt J, Galli-Tsinopoulou A, Wallborn T, Schlicke M, Mü ller E et al. (2010). Heterozygous mutation within a kinaseconserved motif of the insulin-like growth factor I receptor causes intrauterine and postnatal growth retardation. J Clin Endocrinol Metab 95: 1137-1142.
47. Lakin ND, Jackson SP. (1999). Regulation of p53 in response to DNA damage. Oncogene 18: 7644-7655. (Pubitemid 30052691)
48. Laron Z. (2004). Extensive personal experience Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958-2003. J Clin Endocrinol Metab 89: 1031-1044. (Pubitemid 38368385)
49. Laron Z, Weinberger D. (2004). Diabetic retinopathy in two patients with congenital IGF-I deficiency (Laron syndrome). Eur J Endocrinol 151: 103-106. (Pubitemid 39117370)
50. Law JH, Habibi G, Hu K, Masoudi H, Wang MYC, Stratford AL et al. (2008). Phosphorylated insulin-like growth factor-I/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 68: 10238-10246.
51. LeRoith D, Bondy C, Yakar S, Liu J-L, Butler A. (2001). The somatomedin hypothesis: 2001. Endocrine Rev 22: 53-74.
52. LeRoith D, Yakar S. (2007). Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor-1. Nat Clin Pract Endocrinol Metab 3: 302-310.
53. Levine AJ. (1997). p53, the cellular gatekeeper for growth and division. Cell 88: 323-331. (Pubitemid 27131374)
54. Levine AJ, Feng Z, Mak TW, You H, Jin S. (2006). Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev 20: 267-275. (Pubitemid 43200281)
55. Maki RG. (2010). Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. J Clin Oncol 28: 4985-4995.
56. Maor S, Mayer D, Yarden RI, Lee AV, Sarfstein R, Werner H et al. (2006). Estrogen receptor regulates insulin-like growth factor-I receptor gene expression in breast tumor cells: involvement of transcription factor Sp1. J Endocrinol 191: 605-612. (Pubitemid 46210286)
57. Maor S, Papa MZ, Yarden RI, Friedman E, Lerenthal Y, Lee SW et al. (2007a). Insulin-like growth factor-I controls BRCA1 gene expression through activation of transcription factor Sp1. Horm Metab Res 39: 179-185. (Pubitemid 46580615)
58. Maor S, Yosepovich A, Papa MZ, Yarden RI, Mayer D, Friedman E et al. (2007b). Elevated insulin-like growth factor-I receptor (IGFIR) levels in primary breast tumors associated with BRCA1 mutations. Cancer Lett 257: 236-243. (Pubitemid 47538827)
59. Maor SB, Abramovitch S, Erdos MR, Brody LC, Werner H. (2000). BRCA1 suppresses insulin-like growth factor-I receptor promoter activity: potential interaction between BRCA1 and Sp1. Mol Gen Metab 69: 130-136. (Pubitemid 30180697)
60. McKinsey EL, Parrish JK, Irwin AE, Niemeyer BF, Kern HB, Birks DK et al. (2011). A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated micro-RNAs. Oncogene 30: 4910-4920.
61. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S et al. (1994). A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66-71. (Pubitemid 24345325)
62. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M et al. (2004). Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5: 221-230. (Pubitemid 38402114)
63. Nahor I, Abramovitch S, Engeland K, Werner H. (2005). The p53-family members p63 and p73 inhibit insulin-like growth factor-I receptor gene expression in colon cancer cells. Growth Hormone IGF Res 15: 388-396. (Pubitemid 41683806)
64. Nakae J, Kido Y, Accili D. (2001). Distinct and overlapping functions of insulin and IGF-I receptors. Endocrine Rev 22: 818-835. (Pubitemid 34214297)
65. Nana-Sinkam SP, Croce CM. (2011). MicroRNAs as therapeutic targets in cancer. Transl Res 157: 216-225.
66. Narod SA. (2010). BRCA mutations in the management of breast cancer: the state of the art. Nat Rev Clin Oncol 7: 702-707.
67. O'Connor R, Kauffmann-Zeh A, Liu Y, Lehar S, Evan GI, Baserga R et al. (1997). Identification of domains of the insulin-like growth factor I receptor that are required for protection from apoptosis. Mol Cell Biol 17: 427-435. (Pubitemid 26425632)
68. Ohlsson C, Kley N, Werner H, LeRoith D. (1998). p53 regulates IGF-I receptor expression and IGF-I induced tyrosine phosphorylation in an osteosarcoma cell line: interaction between p53 and Sp1. Endocrinology 139: 1101-1107. (Pubitemid 28510128)
69. Pandini G, Mineo R, Frasca F, Roberts Jr CT, Marcelli M, Vigneri R et al. (2005). Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Cancer Res 65: 1849-1857. (Pubitemid 40478613)
70. Peterson JE, Jelinek T, Kaleko M, Siddle K, Weber MJ. (1994). C phosphorylation and activation of the IGF-I receptor in srctransformed cells. J Biol Chem 269: 27315-27321. (Pubitemid 24346553)
71. Plas DR, Thompson CB. (2005). Akt-dependent transformation: there is more to growth than just surviving. Oncogene 24: 7435-7442. (Pubitemid 41637983)
72. Plymate S, Bae V, Madison L, Quinn L, Ware J. (1997). Re-expression of the type I insulin-like growth factor receptor inhibits the malignant phenotype of simian virus 40T antigen inmortalized human prostate epithelial cells. Endocrinology 138: 1728-1735. (Pubitemid 27137128)
73. Pollak M. (2008). Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8: 915-928.
74. Reiss K, Ferber A, Travali S, Porcu P, Phillips PD, Baserga R. (1991). The protooncogene c-myb increases the expression of insulin-like growth factor I and insulin-like growth factor I receptor messenger RNAs by a transcriptional mechanism. Cancer Res 51: 5997-6000.
75. Renehan AG, Frystyk J, Flyvbjerg A. (2006). Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab 17: 328-336. (Pubitemid 44397568)
76. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. (2004). Insulin-like growth factor-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363: 1346-1353. (Pubitemid 38529873)
77. Resnicoff M, Abraham D, Yutanawiboonchai W, Rotman HL, Kajstura J, Rubin R et al. (1995). The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res 55: 2463-2469.
78. Rubinstein M, Idelman G, Plymate SR, Narla G, Friedman SL, Werner H. (2004). Transcriptional activation of the IGF-I receptor gene by the Kruppel-like factor-6 (KLF6) tumor suppressor protein: potential interactions between KLF6 and p53. Endocrinology 145: 3769-3777. (Pubitemid 39037564)
79. Salmon WD, Daughaday WH. (1957). A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med 49: 825-836.
80. Samani AA, Yakar S, LeRoith D, Brodt P. (2007). The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocrine Rev 28: 20-47. (Pubitemid 46220849)
81. Sarfstein R, Belfiore A, Werner H. (2010). Identification of insulin-like growth factor-I receptor gene promoter-binding proteins in estrogen receptor (ER)-positive and ER-depleted breast cancer cells. Cancers 2: 233-261.
82. Schayek H, Bentov I, Rotem I, Pasmanik-Chor M, Ginsberg D, Plymate SR et al. (2010a). Transcription factor E2F1 is a potent transactivator of the insulin-like growth factor-I receptor gene. Growth Hormone IGF Res 20: 68-72.
83. Schayek H, Seti H, Greenberg NM, Sun S, Werner H, Plymate SR. (2010b). Differential regulation of insulin-like growth factor-I receptor gene expression by wild type and mutant androgen receptor in prostate cancer cells. Mol Cell Endocrinol 323: 239-245.
84. Schnarr B, Strunz K, Ohsam J, Benner A, Wacker J, Mayer D. (2000). Down-regulation of insulin-like growth factor-I receptor and insulin receptor substrate-1 expression in advanced human breast cancer. Int J Cancer 89: 506-513.
85. Scotlandi K, Picci P. (2008). Targeting insulin-like growth factor 1 receptor in sarcomas. Curr Opinion Oncol 20: 419-427.
86. Sell C, Dumenil G, Deveaud C, Miura M, Coppola D, DeAngelis T et al. (1994). Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol 14: 3604-3612. (Pubitemid 24160768)
87. Sell C, Rubini M, Rubin R, Liu J-P, Efstratiadis A, Baserga R. (1993). Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci USA 90: 11217-11221. (Pubitemid 23354400)
88. Shackelford DB, Shaw RJ. (2009). The LKB1-AMPK pathway: metabolism and growth control in tumor suppression. Nat Rev Cancer 9: 563-575.
89. Steuerman R, Shevah O, Laron Z. (2011). Congenital IGF1 deficiency tends to confer protection against post-natal development of malignancies. Eur J Endocrinol 164: 485-489.
90. Tang D, Lotze MT, Kang R, Zeh HJ. (2011). Apoptosis promotes early tumorigenesis. Oncogene 30: 1851-1854.
91. Travali S, Reiss K, Ferber A, Petralia S, Mercer WE, Calabreta B et al. (1991). Constitutively expressed c-myb abrogates the requirement for insulin-like growth factor I in 3T3 fibroblasts. Mol Cell Biol 11: 731-736. (Pubitemid 21895421)
92. Ungewitter E, Scrable H. (2010). Delta40p53 controls the switch from pluripotency to differentiation by regulating IGF signaling in ESCs. Genes Dev 24: 2408-2419.
93. Voskuil DW, Bosma A, Vrieling A, Rookus MA, van't Veer LJ. (2004). Insulin-like growth factor system mRNA quantities in normal and tumor breast tissue of women with sporadic and familial breast cancer risk. Breast Cancer Res Treat 84: 225-233. (Pubitemid 38445372)
94. Vousden KH, Ryan KM. (2009). p53 and metabolism. Nat Rev Cancer 9: 691-700.
95. Wallborn T, Wü ller S, Klammt J, Kruis T, Kratzsch J, Schmidt G et al. (2010). A heterozygous mutation of the insulin-like growth factor-I receptor causes retention of the nascent protein in the endoplasmic reticulum and results in intrauterine and postnatal growth retardation. J Clin Endocrinol Metab 95: 2316-2324.
96. Warburg O. (1956). On the origin of cancer cells. Science 123: 309-314.
97. Werner H. (2009). The pathophysiological significance of IGF-I receptor overexpression: new insights. Ped Endocrinol Rev 7: 2-5.
98. Werner H, Bruchim I. (2009). The insulin-like growth factor-I receptor as an onogene. Arch Physiol Biochem 115: 58-71.
99. Werner H, Bruchim I. (2010). Basic and clinical significance of IGF-1-induced signatures in cancer. BMC Med 8: 2.
100. Werner H, Idelman G, Rubinstein M, Pattee P, Nagalla SR, Roberts Jr CT. (2007). A novel EWS-WT1 gene fusion product in desmoplastic small round cell tumor is a potent transactivator of the insulin-like growth factor-I receptor (IGF-IR) gene. Cancer Lett 247: 84-90. (Pubitemid 44959411)
101. Werner H, Karnieli E, Rauscher III FJ, LeRoith D. (1996). Wild type and mutant p53 differentially regulate transcription of the insulinlike growth factor I receptor gene. Proc Natl Acad Sci USA 93: 8318-8323. (Pubitemid 26269555)
102. Werner H, Raizada MK, Mudd LM, Foyt HL, Simpon IA, Roberts Jr CT et al. (1989). Regulation of rat brain/HepG2 glucose transporter gene expression by insulin and insulin-like growth factor-I in primary cultures of neuronal and glial cells. Endocrinology 125: 314-320. (Pubitemid 19182676)
103. Werner H, Re GG, Drummond IA, Sukhatme VP, Rauscher III FJ, Sens DA et al. (1993). Increased expression of the insulin-like growth factor-I receptor gene, IGFIR, in Wilms' tumor is correlated with modulation of IGFIR promoter activity by the WT1 Wilms' tumor gene product. Proc Natl Acad Sci USA 90: 5828-5832. (Pubitemid 23176256)
104. Werner H, Roberts Jr CT. (2003). The IGF-I receptor gene: a molecular target for disrupted transcription factors. Genes Chromosomes Cancer 36: 113-120. (Pubitemid 36109554)
105. Werner H, Shen-Orr Z, Rauscher III FJ, Morris JF, Roberts Jr CT, LeRoith D. (1995). Inhibition of cellular proliferation by the Wilms' tumor suppressor WT1 is associated with suppression of insulin-like growth factor I receptor gene expression. Mol Cell Biol 15: 3516-3522.
106. Wiesener MS, Maxwell PH, Eckardt KU. (2009). New insights into the role of the tumor suppressor von hippel lindau in cellular differentiation, ciliary biology, and cyst repression. J Mol Med 87: 871-877.
107. Yakar S, Pennisi P, Kim CH, Zhao H, Toyoshima Y, Gavrilova O et al. (2005). Studies involving the GH-IGF axis: Lessons from IGF-I and IGF-I receptor gene targeting mouse models. J Endocrinol Invest 26: 19-22. (Pubitemid 46211835)
108. Yang A, McKeon F. (2000). P63 and p73: p53 mimics, menaces and more. Nat Rev 1: 199-207.
109. Yerushalmi R, Gelmon KA, Leung S, Gao D, Cheang M, Pollak M et al. (2011). Insulin-like growth factor receptor (IGF-IR) in breast cancer subtypes. Breast Cancer Res Treat (Epub ahead of print).
110. Yuen JS, Macaulay VM. (2008). Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer. Exp Opinion Ther Targets 12: 589-603. (Pubitemid 351699478)
111. Yuen JSP, Cockman ME, Sullivan M, Protheroe A, Turner GDH, Roberts IS et al. (2007). The VHL tumor suppressor inhibits expression of the IGF1R and its loss induces IGF1R upregulation in human clear cell renal carcinoma. Oncogene 26: 6499-6508. (Pubitemid 47530598)
112. Zalts H, Shomron N. (2011). The impact of microRNAs on endocrinology. Ped Endocrinol Rev 8: 354-362.
113. Zhang L, Kashanchi F, Zhan Q, Zhan S, Brady JN, Fornace AJ et al. (1996). Regulation of insulin-like growth factor II P3 promoter by p53: a potential mechanism for tumorigenesis. Cancer Res 56: 1367-1373. (Pubitemid 26080981)
114. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung MC. (2001). HER-2/neu induces p53 ubiquitination via Akt-mediated Mdm2 phosphorylation. Nat Cell Biol 3: 973-982. (Pubitemid 34428742)